<--- Back to Details
First PageDocument Content
Medicine / Pulmonology / Clinical medicine / Respiratory therapy / Pulmonary function testing / Respiratory physiology / Chronic lower respiratory diseases / Respimat / Thiophenes / Tiotropium bromide / Bronchodilator / Beta2-adrenergic agonist
Date: 2016-08-24 06:15:45
Medicine
Pulmonology
Clinical medicine
Respiratory therapy
Pulmonary function testing
Respiratory physiology
Chronic lower respiratory diseases
Respimat
Thiophenes
Tiotropium bromide
Bronchodilator
Beta2-adrenergic agonist

Microsoft WordSpiriva final redline new IFU.docx

Add to Reading List

Source URL: docs.boehringer-ingelheim.com

Download Document from Source Website

File Size: 501,59 KB

Share Document on Facebook

Similar Documents

Microsoft WordSpiriva final redline new IFU.docx

Microsoft WordSpiriva final redline new IFU.docx

DocID: 1rn7z - View Document

COPD Care Map for Primary Care  Patient Name: ______________________________________ DOB: ________________ Year of diagnosis:___________ Co-morbid conditions:______________________________________________________________

COPD Care Map for Primary Care Patient Name: ______________________________________ DOB: ________________ Year of diagnosis:___________ Co-morbid conditions:______________________________________________________________

DocID: 1qO6l - View Document

Spiriva® Powder for Inhalation (in Capsule) Tiotropium bromide Consumer Medicine Information

Spiriva® Powder for Inhalation (in Capsule) Tiotropium bromide Consumer Medicine Information

DocID: 1fwRM - View Document

BMJ 2011;342:d2970 doi: bmj.d2970  Page 1 of 2 Editorials

BMJ 2011;342:d2970 doi: bmj.d2970 Page 1 of 2 Editorials

DocID: 1aKAn - View Document

KEY ASPECTS 2014   Andreas Barner, Wolfgang Baiker, Allan Hillgrove, Joachim Hasenmaier, Hubertus von Baumbach (from left to right), the Board of Managing Directors  KEY ASPECTS 2014

KEY ASPECTS 2014  Andreas Barner, Wolfgang Baiker, Allan Hillgrove, Joachim Hasenmaier, Hubertus von Baumbach (from left to right), the Board of Managing Directors KEY ASPECTS 2014

DocID: 1atQi - View Document